Optimiser l'usage des médicaments oraux en oncologie: Le cas de l'hormonothérapie adjuvante pour le cancer du sein


Sophie Lauzier

Université Laval


Domaine : cancer

Programme Chercheurs-boursiers - Junior 2

Concours 2019-2020

Adjuvant endocrine therapy (AET) is one of the first oral anticancer medication to have been prescribed. AET is recommended for women with hormone-sensitive breast cancer (75% of women with breast cancer, approximately 15 000 Canadians/year) to reduce recurrence and mortality risks. AET must be taken daily for 5 or 10 years. Despite the widely recognized clinical benefits of AET, suboptimal AET adherence is common. It is estimated that 31 to 47% of women do not persist with AET for the recommended minimum 5 years. Non-adherence to AET has been associated with increased mortality risks and healthcare costs. The ultimate goal of my research program is to contribute to efforts to improve the survivorship experience and breast cancer survival by optimizing the experience with AET and its use.

Four different studies are included in this application. The first one will evaluate the effects of the PAcHA program, a program to be delivered in community pharmacies aiming at enhancing AET adherence. The second study will assess social inequalities in AET use. In the third study, we will identify the best methods to use in research and clinical practice to measure AET use. The last study will be conducted among men who were prescribed an AET after breast cancer to explore their experience with this treatment and identify the most promising strategies to support them. These studies will fill important knowledge gaps. Results and methods will then be used as a model for the study of other oral anticancer medications that are prescribed for several types of cancer.